15 January 2020 - The cost of essential medications for multiple sclerosis have nearly tripled this decade, despite the release of the first generic MS drug, a new study shows.

The 2015 release of glatiramer acetate -- the generic version of Copaxone -- did nothing to halt skyrocketing prices for MS medications, said lead researcher Daniel Hartung. He's an associate professor of pharmacy with Oregon State University, in Portland.

"Overall, there were very minimal effects on the price of all the other medications in the class," Hartung said. "They continued to escalate at about the rate they had before."

Read US News article